Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 12:49PM ET
2.00
Dollar change
+0.08
Percentage change
4.17
%
Index- P/E- EPS (ttm)-5.83 Insider Own69.95% Shs Outstand1.03M Perf Week-31.74%
Market Cap6.50M Forward P/E- EPS next Y-22.20 Insider Trans16.55% Shs Float0.98M Perf Month-48.72%
Income-22.21M PEG- EPS next Q-2.15 Inst Own7.70% Short Float2.86% Perf Quarter-77.19%
Sales0.71M P/S9.15 EPS this Y31.37% Inst Trans- Short Ratio0.01 Perf Half Y-89.64%
Book/sh2.72 P/B0.73 EPS next Y-217.14% ROA-107.90% Short Interest0.03M Perf Year-92.96%
Cash/sh1.65 P/C1.21 EPS next 5Y- ROE-156.05% 52W Range1.62 - 44.00 Perf YTD-85.29%
Dividend Est.- P/FCF- EPS past 5Y-25.24% ROI-267.96% 52W High-95.45% Beta0.51
Dividend TTM- Quick Ratio1.50 Sales past 5Y7.76% Gross Margin-102.12% 52W Low23.46% ATR (14)0.70
Dividend Ex-Date- Current Ratio1.50 EPS Y/Y TTM-13.77% Oper. Margin-2966.01% RSI (14)38.25 Volatility38.00% 29.93%
Employees25 Debt/Eq0.30 Sales Y/Y TTM-41.98% Profit Margin-3132.72% Recom1.00 Target Price30.05
Option/ShortNo / Yes LT Debt/Eq0.21 EPS Q/Q-1103.63% Payout- Rel Volume0.22 Prev Close1.92
Sales Surprise-70.00% EPS Surprise-17.19% Sales Q/Q-47.93% EarningsFeb 27 AMC Avg Volume2.06M Price2.00
SMA20-24.10% SMA50-51.06% SMA200-88.17% Trades Volume241,673 Change4.17%
Apr-19-24 12:13PM
Apr-18-24 04:05PM
Apr-17-24 08:00AM
Apr-16-24 01:08PM
Apr-15-24 08:30AM
08:24AM Loading…
08:24AM
Apr-11-24 05:17PM
Apr-08-24 02:15PM
08:30AM
07:56AM
Mar-19-24 04:01PM
Feb-28-24 10:05AM
09:19AM
Feb-27-24 04:05PM
Feb-21-24 04:05PM
08:00AM Loading…
Jan-29-24 08:00AM
Dec-22-23 04:05PM
Dec-21-23 10:34AM
08:00AM
Dec-20-23 08:00AM
Nov-14-23 08:17AM
Nov-11-23 09:00AM
08:38AM
Nov-10-23 07:30AM
Nov-03-23 08:00AM
Oct-24-23 08:30AM
Oct-13-23 04:05PM
Oct-12-23 08:00AM
Oct-05-23 07:00AM
Sep-12-23 09:00AM
08:00AM Loading…
Sep-11-23 08:00AM
Sep-07-23 08:30AM
08:00AM
Sep-05-23 08:00AM
07:00AM
Aug-29-23 08:00AM
Aug-22-23 08:00AM
Aug-16-23 09:13AM
Aug-14-23 04:05PM
08:00AM
Aug-11-23 07:30AM
07:24AM
07:00AM
Aug-08-23 09:25AM
07:00AM
Aug-07-23 08:00AM
Jul-20-23 08:00AM
Jul-11-23 08:00AM
Jul-10-23 08:00AM
Jul-07-23 09:00AM
Jul-06-23 11:12AM
Jun-27-23 06:07PM
Jun-13-23 08:30AM
May-12-23 08:32AM
08:20AM
08:00AM
May-09-23 05:23PM
08:30AM
May-08-23 08:30AM
Apr-19-23 08:59AM
Mar-14-23 02:38PM
Mar-10-23 08:00AM
06:10AM
Mar-07-23 04:18PM
Mar-06-23 08:30AM
Feb-28-23 08:30AM
Jan-27-23 08:51AM
Jan-19-23 08:35AM
08:30AM
Jan-06-23 09:58AM
08:30AM
Nov-29-22 04:30PM
Nov-16-22 05:32AM
Nov-14-22 08:00AM
07:15AM
Nov-10-22 08:30AM
Nov-07-22 09:06AM
Oct-05-22 02:34PM
11:00AM
08:30AM
Sep-15-22 08:30AM
Sep-06-22 08:30AM
Aug-31-22 08:30AM
07:30AM
Aug-25-22 08:00AM
07:30AM
Aug-20-22 08:45AM
Aug-12-22 08:00AM
07:36AM
Aug-08-22 08:30AM
Jul-27-22 09:33AM
Jul-07-22 08:00AM
Jun-26-22 10:22AM
May-21-22 10:16AM
May-13-22 08:00AM
07:12AM
May-09-22 04:15PM
08:30AM
Apr-28-22 01:53PM
Apr-14-22 08:58AM
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hare JoshuaChief Scientific OfficerApr 11 '24Buy2.3542,553100,000633,280Apr 12 07:00 PM
Soffer RockDirectorApr 11 '24Buy2.3531,91575,000208,534Apr 12 07:00 PM
Hashad Mohamed Wa'el AhmedChief Executive OfficerApr 11 '24Buy2.3510,63824,99919,616Apr 12 07:00 PM
Soffer RockDirectorApr 10 '24Buy2.35106,383250,000176,619Apr 12 07:00 PM
Hare JoshuaChief Scientific OfficerApr 10 '24Buy2.35106,383250,000590,727Apr 12 07:00 PM
Ross CathyDirectorJan 10 '24Buy1.315,0006,54410,000Jan 11 06:00 PM
Baluch KhosoDirectorDec 29 '23Buy1.438,32211,91515,000Jan 02 06:00 PM
PFEFFER JEFFREYDirectorDec 28 '23Buy1.3510,00013,50015,000Dec 29 05:00 PM
Baluch KhosoDirectorDec 28 '23Buy1.401,6782,3426,678Jan 02 06:00 PM
Hare JoshuaChief Scientific OfficerSep 21 '23Option Exercise3.005,00015,0007,828,263Sep 22 07:00 PM
Lehr Paul TGeneral Counsel, SecretarySep 20 '23Option Exercise3.002,0006,000144,213Sep 21 05:00 PM
Hare JoshuaChief Scientific OfficerSep 12 '23Option Exercise3.0030,00090,0007,823,263Sep 14 05:09 PM
Hashad Mohamed Wa'el AhmedChief Executive OfficerSep 12 '23Option Exercise3.0010,00030,00047,566Sep 13 05:00 PM
Soffer RockDirectorSep 08 '23Option Exercise3.0030,00090,000702,351Sep 12 05:00 PM
Clavijo JamesCFO and TreasurerJun 29 '23Sale3.515,00017,55047,303Jun 29 05:00 PM
Clavijo JamesCFO and TreasurerJun 28 '23Sale3.4310,00034,30052,303Jun 29 05:00 PM
Clavijo JamesCFO and TreasurerJun 27 '23Sale3.488,53229,69162,303Jun 29 05:00 PM